drugset / Trial / NCT02289196
Safety Study of Vx006 Vaccine in Solid Tumor Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy \> 6 months; only HLA-A\*02 positive patients. The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-10
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vx-006 | Vaccine | 0.5 mg | Other |
| Subject | Vx-006 | Vaccine | 1 mg | Other |
| Subject | Vx-006 | Vaccine | 5 mg | Other |
| Subject | Vx-006 | Vaccine | 10 mg | Other |